[
    [
        {
            "time": "2018-01-02",
            "original_text": "Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study",
            "features": {
                "keywords": [
                    "MRK",
                    "SNY",
                    "Cancer Firms",
                    "LLY",
                    "Lung Cancer Study"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Boehringer Ingelheim and Lilly provide update on Jardiance速 phase III exercise ability studies in chronic heart failure",
            "features": {
                "keywords": [
                    "Boehringer Ingelheim",
                    "Lilly",
                    "Jardiance",
                    "phase III",
                    "chronic heart failure"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Boehringer Ingelheim and Lilly provide update on Jardiance速 phase III exercise ability studies in chronic heart failure",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "What to Do with Karuna Stock After It Soared and Then Plunged",
            "features": {
                "keywords": [
                    "Karuna",
                    "Soared",
                    "Plunged"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "What to Do with Karuna Stock After It Soared and Then Plunged",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "CHMP Issues Positive Opinion to Expand CYRAMZA速 (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
            "features": {
                "keywords": [
                    "CHMP",
                    "CYRAMZA",
                    "ramucirumab",
                    "RELAY Study",
                    "EGFR-Mutated",
                    "Non-Small Cell Lung Cancer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CHMP Issues Positive Opinion to Expand CYRAMZA速 (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]